Association of CD209L tandem repeats polymorphism with susceptibility to human immunodeficiency virus-1 infection, disease progression, and treatment outcomes: a Moroccan cohort study  by Fayssel, N. et al.
RESEARCH NOTE VIROLOGYAssociation of CD209L tandem repeats
polymorphism with susceptibility to human
immunodeﬁciency virus-1 infection, disease
progression, and treatment outcomes: a
Moroccan cohort studyN. Fayssel1, R. Bensghir2, A. Ouladlahsen2, H. Abdelghaffar3,
M. Sodqi2, K. Lahlou1, S. Benjelloun4, K. Marhoum El Filali2,
S. Ezzikouri4 and L. Wakrim1
1) Virology Unit, Immunovirology Laboratory, Pasteur Institute of Morocco,
Casablanca, 2) Laboratoire de Biochimie, Environnement & Agroalimentaire,
Université Hassan II, Facultédes Sciences et Techniques, Mohammedia-
Casablanca, 3) Service des Maladies Infectieuses, CHU Ibn
Rochd and 4) Virology Unit, Viral Hepatitis Laboratory, Pasteur Institute of
Morocco, Casablanca, MoroccoAbstractIn order to investigate the association between length variation of the
CD209L neck region and human immunodeﬁciency virus (HIV)-1
susceptibility, disease progression, and treatment response
outcomes, we genotyped 139 HIV-1-seropositive and 109
seronegative individuals. The heterozygous genotype 6/5 showed a
signiﬁcant increased risk of HIV-1 infection (OR 3.03, 95% CI
0.99–9.33, p 0.046). Moreover, after highly active antiretroviral
therapy (HAART), HIV-1-seropositive individuals carrying the 6/5,
7/5 and 7/7 genotypes and alleles 5, 6 and 7 showed good CD4+
T-cell recovery. In addition, individuals with the 7/5, 6/6 and 7/7
genotypes showed a signiﬁcant decrease in viral load during the
treatment period as compared with baseline (p < 0.05).
Interestingly, we found that alleles 4 and 6 were associated with
protection against AIDS progression. D209L variation may
inﬂuence susceptibility to HIV-1, response to treatment, and
disease progression.
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S. Ezzikouri and L. Wakrim contributed equally to this workIntroductionAccording to the recent UNAIDS report, 35.3 (32.2–38.8)
million people were living with human immunodeﬁciency virus
(HIV) and 2.3 (1.9–2.7) million became newly infected with HIV
in 2013 [1]. In Morocco, the scale of the local HIV epidemics and
populations affected showed a highly heterogeneous geograph-
ical distribution [2]. Patients infected with HIV-1 show variable
clinical outcomes. This natural variation can be attributed to host
genetics, pathogen factors, and environmental factors, and is
substantial among infected individuals [3,4]. Early studies showed
that liver– lymph node-speciﬁc intercellular adhesion molecule-3
(ICAM-3)-grabbing integrin (L-SIGN), also known as dendritic
cell-speciﬁc ICAM-3-grabbing non-integrin-related (DC-SIGNR)
or CD209L, might promote the spread of HIV infection in lymph
nodes [5,6]. The CD209L gene is highly polymorphic in the neck
region; this is responsible for the homo-oligomerization that
brings carbohydrate recognition domains (CRDs) into proximity
for high-afﬁnity ligand binding, based on the number of repeats in
exon 4, with three to ten repeats (alleles 3 to 10) of a 69-bp
segment [5,7–9]. Previous studies have shown that CD209L
captures HIV-1 by binding to glycoprotein 120, and promotes
the enhancement of T-cell infection by HIV-1 in trans [5,6] and
also virus degradation in a proteasome-dependent manner [10].
Previous studies on the association between variation in the neck
region of CD209L and HIV-1 susceptibility have been conducted,
with controversial results [11–13]. In addition, the association
between CD209L neck-repeat length and the response to highly
active antiretroviral therapy (HAART) has not been investigated
so far. Therefore, the aim of our study was to investigate the
associations between length variation of the CD209L neck region
and HIV-1 susceptibility, disease progression and treatment
response outcomes in Moroccan subjects, a North African
population.
The cohort was established in September 2012, with 139
antiretroviral-naive HIV-1-seropositive adult subjects (80
women (57.6%); 59 men (42.4%)). All patients are nowClin Microbiol Infect 2015; 21: 513.e1–513.e5
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nevirapine or lopinavir/ritonavir or efavirenz. One hundred and
nine unrelated HIV-negative healthy subjects were recruited as
described previously [14]. The CD209L repeat region was
genotyped as reported previously [14].
The characteristics and allele and genotype frequencies of
the study subjects are summarized in Table 1.The analysis of the
frequency distribution of the CD209L neck-region genotypes
showed that the frequency of the 6/5 genotype was signiﬁcantly
different between the seronegative and HIV-1-seropositive
subjects (4.6% vs. 9.3%, p 0.046). Logistic regression analysis
of the association of genotype with susceptibility to HIV-1
demonstrated that the 6/5 genotype was the only genotype
signiﬁcantly associated with the risk of infection with HIV-1
(OR 3.03, 95% CI 0.99–9.33, p 0.046) (Table 1).
At baseline, we found no association between any CD209L
genotype and CD4+ T-cell counts (all p > 0.05) (Fig. 1(a)).
However, during follow-up and after HAART, the CD4+ T-cell
count was associated with the CD209L genotypes (Fig. 1(a)).
Overall, HIV-1-seropositive subjects carrying genotypes 6/5
(449 cells/mm3 at baseline vs. 608 cells/mm3 after HAART, p
0.015), 7/5 (280 cells/mm3 at baseline vs. 358 cells/mm3after
HAART, p 0.001) and 7/7 (346 cells/mm3 at baseline vs. 463
cells/mm3 after HAART, p 0.001) had an attenuated loss of
CD4+ T-cells, with a signiﬁcant increase in the numbers of cells
as compared with baseline CD4+ T-cell levels (Fig. 1(a)).
Regarding allele frequencies, we found that alleles 5 (329 cells/
mm3 at baseline vs. 409 cells/mm3 after HAART, p < 0.0001), 6
(402 cells/mm3 at baseline vs. 489 cells/mm3 after HAART, pTABLE 1. Demographic, clinical characteristics and liver–lymph no
(L-SIGN) neck-region polymorphism of the study subjects
HIV-1-seropositive subjects (n
Mean age ± SD (years) 37.62 ± 9.63
Gender (male/female) 60/79
Baseline median CD4+ T-cell count ± SD (cells/mm3) 348 ± 317
Baseline median viral load ± SD (log10 copies/mL) 4.59 ± 1.30
Median antiretroviral treatment in months (range) 9 (1–14)
Fraction of patients who progress to AIDS 0.52
Genotypes
4/4 1 (0.7)
5/4 0 (0)
6/4 3 (2.1)
7/4 4 (2.9)
5/5 12 (8.6)
6/5 13 (9.3)
7/5 32 (23)
6/6 8 (5.7)
7/6 24 (17.3)
7/7 42 (30.2)
Homozygotes 63 (45.3)
Heterozygotes 76 (54.7)
L-SIGN alleles n = 278
4 9 (3.2)
5 69 (24.8)
6 56 (20.1)
7 144 (51.8)
SD, standard deviation.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect0.005) and 7 (330 cells/mm3 at baseline vs. 429 cells/mm3 after
HAART, p < 0.0001) were associated with restoration of CD4+
T-cells as compared with allele 4, which was not associated with
a signiﬁcant increase in the number of CD4+ T-cells after
HAART (392 cells/mm3 at baseline vs. 463 cells/mm3 after
HAART, p 0.5277) (Fig. 1(b)).
On the other hand, at baseline, no association was observed
between any CD209L genotype and HIV-1 RNA viral load (all
p > 0.05) (Fig. 1(c)). However, after HAART, subjects with the
7/5 genotype reduced their HIV-1 RNA viral load (4.75 log10 vs.
3.1 log10 copies/mL, p 0.0003) more than those with genotype
7/6 (4.8 log10 vs. 3.6 log10 copies/mL, p 0.0366) and genotype 7/
7 (4 log10 vs 3 log10 copies/mL, p 0.0050) (7/5 > 7/7 > 7/6)
(Fig. 1(c)). Moreover, after HAART, a signiﬁcant correlation
was found between CD209L alleles and HIV-1 viral load. Sub-
jects with alleles 5, 6 and 7 showed a signiﬁcant reduction in
viral load as compared with subjects with allele 4 (Fig. 1(d)).
We checked whether the frequency distributions of CD209L
neck-region genotypes and alleles were signiﬁcantly different
between patients with and without AIDS progression
(Table S1). Progression to AIDS in adults was deﬁned according
to the CDC classiﬁcation when patients showed opportunistic
infections and the CD4 count was <200 cells/mm3. Analysis of
the association of genotype with progression outcomes
demonstrated that only the 5/5 genotype increased the risk of
progression to AIDS, without reaching the signiﬁcance
threshold (p 0.093, OR 3.3, 95% CI 0.78-13.93) (Table S1). In
addition, comparison between the non-progressor and pro-
gressor groups carrying or not carrying allele 4 showed that thisde-speciﬁc intercellular adhesion molecule-3-grabbing integrin
[ 139) Seronegative subjects (n [ 109) OR (95% CI) p
56.45 ± 10.86 — —
53/56 — —
— — —
— — —
— — —
— — —
2 (1.8) 0.42 (0.04–4.92) 0.484
1 (0.9) 0.29 (0.01–7.24) 0.284
0 (0) 0.12 (0.01–2.45) 0.067
6 (5.5) 1.28 (0.34–4.92) 0.713
7 (6.4) 1.51 (0.38–6.09) 0.556
5 (4.6) 3.03 (0.99–9.33) 0.046
20 (18.3) 0.71 (0.22–2.27) 0.568
7 (6.9) 0.75 (0.25–2.27) 0.610
25 (22.9) 1.18 (0.57–2.37) 0.671
36 (33) 1.00 —
52 (47.7) — —
57 (52.3) 0.91 (0.53–1.55) 0.798
n = 218
11 (5) 0.63 (0.23–1.67) 0.361
40 (18.3) 1.47 (0.93–2.33) 0.080
44 (20.2) 1.00 (0.63–1.59) 0.991
123 (56.4) 0.83 (0.57–1.20) 0.319
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FIG. 1. CD4+ T-cell counts and human immunodeﬁciency virus (HIV)-1 RNA viral load according to CD209L neck-repeat variation. (a) Association
between genotypes of CD209L and CD4+ T-cell counts. (b) The improvement in CD4+ T-cell counts between the initial and ﬁnal measurements after
highly active antiretroviral therapy (HAART) according to alleles of CD209L. For all graphs, error bars represent mean ± standard error of the mean
(SEM). (c) HIV-1 RNA viral load according to CD209L genotype at baseline and after HAART. (d) Impact of CD209L alleles on HIV-1 RNA viral load
outcomes after HAART. For all graphs, error bars represent mean ± SEM.
CMI Fayssel et al. Inﬂuence of L-SIGN polymorphism on HIV-1 infection 513.e3allele was more prevalent in the non-progressor group than in
the progressor group (5.3% vs. 1.4%, respectively, p 0.02).
Moreover, we found that the prevalence of allele 6 was signif-
icantly much high in the non-progressor group than in the
progressor group (22% vs. 18.5%, respectively, p 8 × 10−3)
(Table S1).
In the present study, we found that, overall, the heterozygous
6/5 genotype was associated with HIV-1 susceptibility. However,
previous studies demonstrated that the homozygous 7/7 geno-
type was signiﬁcantly associated with an increased risk of HIV-1
infection, whereas the heterozygous 7/5 genotype was corre-
lated with relative resistance to HIV-1 infection [12,13,15].
Moreover, a previous study showed that the medium length
6-tandem or 7-tandem repeats form a rigid neck region that
projects the carbohydrate recognition domains away from theClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Inmembrane, ensuring strong multivalent adhesion to the target
membrane, and thus promoting access to pathogens [16].
We also showed that, at baseline prior to initiation of
treatment, there was no association between the number of
CD209L repeats and viral load. However, Xu et al. found that
patients with the DC-SIGNR 9/7 or 7/7 genotype had signiﬁ-
cantly higher HIV RNA loads than those with the 7/5 genotype
[17]. Interestingly, our work suggests that variation in the
number of CD209L repeats was linked to HIV viraemia after
HAART.
Furthermore, we found that variation in CD209L genotypes/
alleles was not associated with CD4+ T-cell numbers at baseline.
This ﬁnding seems to be in accordance with a previous study, in
which no signiﬁcant differences were found between CD4+ T-
cells in patients with different CD209L genotypes/alleles [17].fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 513.e1–513.e5
513.e4 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIHowever, after HAART, the CD4+ T-cell counts were associ-
ated with CD209L genotypes/alleles. Thus, our preliminary evi-
dence suggests that the neck-region variation of CD209L may
explain why the majority of patients have evidence of slow in-
creases in their CD4+ T-cell count over time, but many do not.
Moreover, most patients with CD209L genotypes that showed
reduction in HIV-1 viraemia after HAART are able to increase
their CD4+ T-cell counts. Studies that have addressed the pre-
dictors of discordant responses (with virological suppression
but incomplete CD4+ T-cell recovery) have shown different
results. Among patients with HIV-1 infection, a substantial
proportion (10–30%) of individuals showed complete or partial
CD4+ T-cell recovery while on HAART, despite suppression of
HIV-1 viraemia to undetectable levels [18]. Therefore, further
investigations are needed to conﬁrm these ﬁndings and elucidate
the molecular basis of CD4+ T-cell recovery variation. In this
study, we found that mainly allele 6 of CD209L was associated
with protection against disease progression to AIDS. Moreover,
it is conceivable that receptors with fewer repeats form smaller
oligomers and are less effective in binding to target molecules
such as HIV-1 glycoprotein 120 [19].
In conclusion, CD209L gene variation seems to be an
important factor affecting the host’s susceptibility to HIV-1
infection and progression to AIDS. Furthermore, we found,
for the ﬁrst time, that the number of CD209L repeats inﬂuences
CD4+ T-cell counts and HIV-1 RNA viral load after the start of
HAART, and could potentially help to guide treatment strate-
gies. However, owing to the small sample size and differences in
allele frequencies worldwide, other investigations are war-
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